CORT analyst estimates

Corcept Therapeutics (CORT) analyst ratings, the average price target and its range, and every firm's latest call.

CORT analyst ratings and price targets

DateFirmCallTarget
Aug 18, 2026Truist FinancialTruist Securities Assumes Corcept Therapeutics (CORT) at Buy$164.00
Jul 30, 2026H.C. WainwrightCorcept Therapeutics (CORT) PT Raised to $165 at H.C. Wainwright$165.00
Jul 29, 2026Canaccord GenuityCorcept Therapeutics price target raised to $150 from $135 at Canaccord$150.00
Jul 27, 2026Wolfe ResearchCorcept Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research$50.00
Jun 2, 2026H.C. WainwrightH.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT)$95.00
May 28, 2026UBSCorcept Therapeutics price target raised to $135 from $110 at Canaccord$135.00
May 13, 2026UBSCorcept Therapeutics upgraded to Buy from Neutral at UBS$72.00
May 4, 2026H.C. WainwrightCorcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright$75.00
May 1, 2026Piper SandlerCorcept Therapeutics price target raised to $88 from $73 at Piper Sandler$88.00
Feb 20, 2026H.C. WainwrightCorcept Therapeutics price target lowered to $67 from $105 at H.C. Wainwright$67.00
Jan 23, 2026Canaccord GenuityCorcept Therapeutics price target raised to $100 from $99 at Canaccord$100.00
Jan 22, 2026H.C. WainwrightCorcept Therapeutics price target raised to $105 from $90 at H.C. Wainwright$105.00
Jan 2, 2026Canaccord GenuityCorcept Therapeutics (CORT) PT Lowered to $99 at Canaccord Genuity$99.00
Jan 2, 2026H.C. WainwrightCorcept Therapeutics (CORT) PT Lowered to $90 at H.C. Wainwright$90.00
Dec 31, 2025Truist FinancialCorcept Therapeutics price target lowered to $50 from $135 at Truist$50.00

Updated 2026-11-02 23:10 UTC